Perrigo furthers commitment to Ireland
Dublin headquarters central to European and global growth strategy.
Perrigo Company has announced that a number of key public facing corporate functions will be relocated to Ireland as part of the company's focused international growth strategy and global expansion. This announcement furthers the company's previously announced actions on 22 October 2015 to maximize efficiency and continue leveraging the strength of Perrigo's global platform. A number of positions will also be added to the company's Dublin headquarters across a range of corporate functions including supply chain/global operations, procurement, enterprise risk management and corporate finance and information technology.
Perrigo has long identified Ireland as a gateway for its expansion into Europe. The acquisition of Omega Pharma in 2015, which added a pan-European branded consumer healthcare platform, the transfer of major corporate functions to Ireland, and the expansion of the Company's headquarters underscores Perrigo's commitment to European and international growth.
As part of this expansion, Arthur Shannon will relocate to Ireland and assume the role of Vice President, Global Corporate Affairs and European Investor Relations. In this role Mr Shannon will continue to oversee both internal and external Global Communications and will continue to be the lead point of contact for media. In addition, he will now be responsible for establishing a global government relations base from Dublin and expanding Perrigo's already robust, shareholder focused Investor Relations programs across Europe. Mr Shannon will be moving to Dublin in early April. At that time we will update his contact information.
Separately, Bradley Joseph has been promoted to the role of Vice President, Global Investor Relations. Mr Joseph will lead the investor relations team in designing and executing the relevant strategies, communications and investor outreach programs for the globe. He will continue to be based in Allegan, Michigan.
In addition, Lou Cherico, Vice President, Corporate Treasurer, will relocate to Dublin, to accelerate the buildout of Perrigo's Global Treasury and Risk Management functions in Ireland to better support our international expansion.
Msr. Shannon, Joseph and Cherico will report directly to Judy Brown, Executive Vice President and Chief Financial Officer at Perrigo.
Joe Papa, Chairman and CEO of Perrigo commented: "We are delighted to announce the addition of these key external facing corporate functions to our Dublin base, reinforcing our plans to expand our footprint in Ireland. These additions build on the outstanding Dublin based team currently in place. We are excited about this next chapter in our international growth. The enhancement of our Irish operations furthers the benefits of our global platform and will enable us to drive continued strong profit growth and enhance shareholder value."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.